SCYNEXIS (SCYX)

• Market cap: $37.9M
• 1 day: -1.00%
• 5 days: -12.29%
• 1 month: -15.26%
• 3 months: -35.90%
• 6 months: -46.81%
• Year to date: -54.76%
• 1 year: -45.95%
• 5 years: -86.19%
• 10 years: -99.01%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Employees: 29

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,460% more call options, than puts

Call options by funds: $78K | Put options by funds: $5K

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

2.05% less ownership

Funds ownership: 36.82% [Q2] → 34.77% (-2.05%) [Q3]

19% less funds holding

Funds holding: 54 [Q2] → 44 (-10) [Q3]

30% less capital invested

Capital invested by funds: $27.8M [Q2] → $19.6M (-$8.21M) [Q3]

71% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 14